RCEL logo

AVITA Medical (RCEL) Company Overview

Profile

Full Name:

AVITA Medical, Inc.

Sector:

Healthcare

Country:

United States

IPO:

May 14, 2012

Indexes:

Not included

Description:

RCEL, a product of AVITA Medical, focuses on advanced regenerative medicine. It offers innovative solutions for wound care and skin regeneration, using a unique technology that harnesses the body’s own healing abilities. Their products aim to improve patient outcomes and enhance recovery processes in healthcare settings.

Events Calendar

Earnings

Next earnings date:

Feb 13, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Feb 22, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jun 30, 2020

Analyst ratings

Recent major analysts updates

Jan 8, 25 Lake Street
Buy
Jan 8, 25 D. Boral Capital
Buy
Dec 24, 24 D. Boral Capital
Buy
Dec 24, 24 Cantor Fitzgerald
Overweight
Nov 8, 24 Piper Sandler
Neutral
Aug 9, 24 Cantor Fitzgerald
Overweight
May 14, 24 Piper Sandler
Neutral
May 14, 24 Cantor Fitzgerald
Overweight
Apr 11, 24 BTIG
Neutral
Feb 23, 24 Piper Sandler
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Investors Burned By AVITA Medical's Sales Miss: I'm Even More Bullish
Investors Burned By AVITA Medical's Sales Miss: I'm Even More Bullish
Investors Burned By AVITA Medical's Sales Miss: I'm Even More Bullish
RCEL
seekingalpha.comJanuary 12, 2025

AVITA Medical's stock plummeted 36.4% after a significant Q4 sales miss, highlighting a pattern of guidance misses. Management's breakeven target shifted to Q4 2025. It also gave 2025 sales guidance of $100-$106 million. The Company will be forced to repay its $40 million OrbiMed loan if its sales follow my projections and company guidance.

AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini
AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini
AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini
RCEL
seekingalpha.comJanuary 10, 2025

AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini

Avita Medical Cuts Annual Sales Forecast On Softer Demand From Hospitals
Avita Medical Cuts Annual Sales Forecast On Softer Demand From Hospitals
Avita Medical Cuts Annual Sales Forecast On Softer Demand From Hospitals
RCEL
benzinga.comJanuary 8, 2025

On Tuesday, Avita Medical, Inc. RCEL revised its revenue guidance for the fourth quarter and full year of 2024.

AVITA Medical's shares sink 19% after another forecast cut
AVITA Medical's shares sink 19% after another forecast cut
AVITA Medical's shares sink 19% after another forecast cut
RCEL
reuters.comJanuary 7, 2025

AVITA Medical's Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in 15 months, after the regenerative medicine firm cut its forecast for the fourth time in five quarters and pushed out its profitability target.

AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance
AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance
AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance
RCEL
globenewswire.comJanuary 7, 2025

AVITA Medical expects fourth quarter 2024 commercial revenue of approximately $18.4 million, reflecting growth of around 30% over the same period in 2023.

AVITA Medical Just Tripled Its TAM In The Burn Market
AVITA Medical Just Tripled Its TAM In The Burn Market
AVITA Medical Just Tripled Its TAM In The Burn Market
RCEL
seekingalpha.comJanuary 2, 2025

AVITA Medical's Q3 report showed strong sequential sales growth and a lower burn rate. My confidence in it reaching breakeven by Q3 2025 has increased. The transition to RECELL GO has been highly successful, with 75% of the US sales base switching from the manual version. This is driving increased utilization. The total addressable market for AVITA's new ecosystem of products has expanded significantly, with the burning market TAM increasing from $450 million to $1.5 billion.

AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds
AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds
AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds
RCEL
globenewswire.comDecember 23, 2024

VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for RECELL GO® mini.

AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market
AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market
AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market
RCEL
globenewswire.comDecember 19, 2024

New collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDerm Cohealyx expected to triple AVITA Medical's addressable market in burns VALENCIA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Cohealyx™, a new collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences.

AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
RCEL
globenewswire.comNovember 25, 2024

VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 11:30 a.m. Eastern Time.

AVITA Medical, Inc. (RCEL) Q3 2024 Earnings Call Transcript
AVITA Medical, Inc. (RCEL) Q3 2024 Earnings Call Transcript
AVITA Medical, Inc. (RCEL) Q3 2024 Earnings Call Transcript
RCEL
seekingalpha.comNovember 9, 2024

AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Ross Osborne - Cantor Fitzgerald Eric Anderson - TD Cowen John Hester - Bell Potter Chris Kallos - MST Access Operator Good day and thank you for standing by. Welcome to the AVITA Medical, Inc. Third Quarter 2024 Earnings Conference Call.

FAQ

  • What is the ticker symbol for AVITA Medical?
  • Does AVITA Medical pay dividends?
  • What sector is AVITA Medical in?
  • What industry is AVITA Medical in?
  • What country is AVITA Medical based in?
  • When did AVITA Medical go public?
  • Is AVITA Medical in the S&P 500?
  • Is AVITA Medical in the NASDAQ 100?
  • Is AVITA Medical in the Dow Jones?
  • When was AVITA Medical's last earnings report?
  • When does AVITA Medical report earnings?
  • Should I buy AVITA Medical stock now?

What is the ticker symbol for AVITA Medical?

The ticker symbol for AVITA Medical is NASDAQ:RCEL

Does AVITA Medical pay dividends?

No, AVITA Medical does not pay dividends

What sector is AVITA Medical in?

AVITA Medical is in the Healthcare sector

What industry is AVITA Medical in?

AVITA Medical is in the Medical Devices industry

What country is AVITA Medical based in?

AVITA Medical is headquartered in United States

When did AVITA Medical go public?

AVITA Medical's initial public offering (IPO) was on May 14, 2012

Is AVITA Medical in the S&P 500?

No, AVITA Medical is not included in the S&P 500 index

Is AVITA Medical in the NASDAQ 100?

No, AVITA Medical is not included in the NASDAQ 100 index

Is AVITA Medical in the Dow Jones?

No, AVITA Medical is not included in the Dow Jones index

When was AVITA Medical's last earnings report?

AVITA Medical's most recent earnings report was on Nov 7, 2024

When does AVITA Medical report earnings?

The next expected earnings date for AVITA Medical is Feb 13, 2025

Should I buy AVITA Medical stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions